Cantor lifts Ultragenyx price target after FDA Fayuvi approval
TradingView News reports Cantor raised its price target after the U.S. FDA approved Fayuvi to treat children with Sanfilippo syndrome Type A; Ultragenyx (RARE) was in focus amid “price-target hikes.”
Ultragenyx Pharmaceutical (RARE) drew attention on Friday after several analysts raised price targets following U.S. Food and Drug Administration (FDA) approval of Fayuvi for children with Sanfilippo syndrome Type A. The approval follows a major setback for the company just weeks earlier.